[A case of marked eosinophilia in peripheral blood induced by rhGM-CSF].
A 53-year-old man underwent chemotherapy (CDDP, VDS, MMC) for treatment of lung cancer. He was given 125 micrograms/m2 of GM-CSF subcutaneously every day for 8 consecutive days, in order to prevent neutropenia. Three days after starting GM-CSF therapy, marked eosinophilia in peripheral blood was observed. The maximum eosinophil count was 89% of leukocytes. Nine days after stopping the treatment with GM-CSF, the number of eosinophils had normalized spontaneously. There were no clinical symptoms except for slight fever, up to 37.5 degrees C. Moreover, there was no relationship between the number of eosinophils and the serum levels of cytokines (IL-3, IL-5, GM-CSF), although we observed minimal but significant elevation of serum ECP level. This case indicates that GM-CSF may induce marked eosinophilia rather than widely stimulating granulocytes and monocytes.
Sawamoto
S
S
Second Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Nomoto
H
H
Yamada
K
K
Kawashima
R
R
Makino
K
K
Nakagome
K
K
Takei
T
T
Mizobe
M
M
Ohta
K
K
Mano
K
K
D001798:Blood Proteins / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D016207:Cytokines / Q000097:blood; D047091:Eosinophil Granule Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000517:prevention & control; D011657:Pulmonary Eosinophilia / Q000209:etiology*; D012260:Ribonucleases
D001798:Blood Proteins; D016207:Cytokines; D047091:Eosinophil Granule Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D012260:Ribonucleases